Company news

Radiopharm Theranostics Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Radiopharm Theranostics Doses First Patient in Phase 1 ‘HEAT’ Trial of 177Lu-RAD202 for Treatment of Advanced HER2-Positive Solid Tumors

June 4, 2025

RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

June 3, 2025

Radiopharm Theranostics Reports Preclinical Lu177-B7H3-mAb Data Demonstrating Favourable Biodistribution and High Tumour Uptake

June 2, 2025

RAD Reports Positive Preclinical Lu177-B7H3-mAb Data

June 1, 2025

ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177

May 19, 2025

Radiopharm Theranostics Accelerates 177Lu-RAD204 Phase 1 Dose Escalation Clinical Trial Based on Positive Recommendation from Data Safety and Monitoring Committee (DSMC)

May 12, 2025

Acceleration of RAD204 Phase 1 dose escalation trial

May 11, 2025

Radiopharm Theranostics to Participate in the D. Boral Capital Inaugural Global Conference

May 7, 2025

Radiopharm Theranostics Doses First Patient with 18F-RAD101 in U.S. Phase 2b Imaging Study of Brain Metastasis

April 28, 2025

First patient dosed in Phase IIb imaging for Brain Mets

April 27, 2025

New RAD202 data confirms positive tumor uptake

March 16, 2025

Half Year Report and Appendix 4D 31 December 2024

February 28, 2025

Clinical trial data shows RAD 101 detects Brain Metastases

February 9, 2025

Lantheus increases shareholding in RAD with A$8m placement

January 9, 2025

Strategic Co-Development Partnership with Lantheus for Aus

December 29, 2024

RAD 202 receives approval to start Phase 1 therapeutic trial

December 19, 2024

Response to ASX Aware Letter

December 18, 2024

Completion of preclinical data package for RAD 402

December 9, 2024

Approval received to expand RAD204 Phase 1 trial

November 19, 2024

RAD 301 shows strong imaging potential in pancreatic cancer

November 17, 2024

RAD increases ownership in Radiopharm Ventures to 75%

August 25, 2024

FDA IND approval for Phase 2b trial in brain metastases

July 22, 2024

First patient dosed in Phase 1 therapeutic lung cancer trial

July 10, 2024

Reinstatement to Quotation

June 25, 2024

Radiopharm Theranostics completes A$70 million placement

June 25, 2024

Suspension from Quotation

June 23, 2024

Radiopharm Receives Strategic Investment for up to A$18 mill

June 20, 2024

Half Yearly Report and Accounts

February 29, 2024

Dosing begins in Phase 1 Pancreatic Imaging Study of RAD 301

February 28, 2024

Pilot Study Validates RAD Terbium-161 Radiotherapeutics

February 27, 2024

Radiopharm receives $1.9 M advance on FY24 R&D tax incentive

February 20, 2024

RAD secures Share Facility Agreement of up to A$12.5m

February 5, 2024

RAD 502 can halt tumour progression and prolong survival

February 4, 2024

Placement of Entitlement Offer Shortfall

January 23, 2024

2nd Australian site for Nanomab-PDL-1 Phase 1 trial

December 26, 2023

Phase 1 Therapeutic NSCLC (Lung Cancer) Trial Opens 4 Jan

December 21, 2023

Completion of Entitlement Offer

December 8, 2023

Radiopharm receives $4.85M R&D tax incentive

November 20, 2023

Entitlement Offer Documents

November 7, 2023

Entitlement Offer to raise approximately $10 million

October 30, 2023

FDA green light for diagnostic Phase 1 pancreatic trial

October 16, 2023

RAD receives approval for Phase 1 therapeutic study of NSCLC

October 8, 2023

Appendix 4E and FY23 Financial Report

August 31, 2023

TerThera Terbium-161 isotope supply agreement expanded

August 24, 2023

FDA Pre-IND meeting supports an IND application for RAD 101

May 29, 2023

RAD 301 receives FDA Orphan Drug Designation

May 9, 2023

Agreement with TerThera to supply Terbium-161 isotope

April 17, 2023

Radiopharm to acquire Pharma15 Corporation

March 2, 2023

Appendix 4D and Half Year Report

February 28, 2023

Radiopharm Theranostics initiates process for Nasdaq listing

February 13, 2023

← Newer news releases · Older news releases →

Decks

The 5 newest of 28 decks. Every deck is listed under its year.